Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF)

Bibliographic Details
Title: Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF)
Authors: Lamyaa Elsayed Allam, Ahmed Aly Abdelmotteleb, Hayam Mohamed Eldamanhoury, Hassan Shehata Hassan
Source: The Egyptian Heart Journal, Vol 76, Iss 1, Pp 1-9 (2024)
Publisher Information: SpringerOpen, 2024.
Publication Year: 2024
Collection: LCC:Diseases of the circulatory (Cardiovascular) system
Subject Terms: Sacubitril/valsartan combination, ECG, Echocardiography, Heart failure, Reduced ejection fraction, Diseases of the circulatory (Cardiovascular) system, RC666-701
More Details: Abstract Background Sacubitril/valsartan therapy has been found to reduce hospitalizations, improve echocardiogram parameters, and improve mortality in HFrEF. The objective is to assess S/V therapy effect on electrocardiogram indices and how those parameters related to echocardiographic parameters. Results From June 2022 until June 2023, this prospective study enrolled 100 patients (mean age 56.1, 8.2, 78% male) with non-ischemic dilated cardiomyopathy (NIDCM) used PARADIGM-HF criteria: NYHA Class II, III, or IV HF; ejection fraction EF ≤ 40%; and hospitalization for HF within previous 12 months. Before starting S/V therapy, an echo and ECG were performed, as well as 6 months following the optimal dose and if LVEF was improved by more than 5%, they were termed notable S/V treatment responders. Aside from improving echo parameters, ECG parameters improved significantly. The QRS width was reduced from 123.7 ± 20.3 to 117.1 ± 18.8 ms (p 0.00), and QTc interval was reduced from 425.4 ± 32.8 to 421.4 ± 32.3 ms (p = 0.012). QRS width was significantly reduced in patients with LBBB, RBBB, and IVCD based on QRS morphology. QRS width (r = − 0.243, p = 0.016) and QTc (r = − 0.252, p = 0.012) had a negative connection with LVEF. Conclusion S/V therapy, in addition to improving echo parameters and NYHA class, improves QRS width and corrected QTc interval on ECG in HFrEF patients. This is an indication of reverse electrical LV remodeling and can be used as an auxiliary prediction for tracking therapy outcomes.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2090-911X
Relation: https://doaj.org/toc/2090-911X
DOI: 10.1186/s43044-024-00468-4
Access URL: https://doaj.org/article/3ffc14d7d22745b3a49e92a9117b60ae
Accession Number: edsdoj.3ffc14d7d22745b3a49e92a9117b60ae
Database: Directory of Open Access Journals
More Details
ISSN:2090911X
DOI:10.1186/s43044-024-00468-4
Published in:The Egyptian Heart Journal
Language:English